SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Witjes JA, Kiemeney LA, Oosterhof GO, Debruyne FM. Prognostic factors in superficial bladder cancer. A review. Eur Urol 1992; 21: 8997
  • 2
    Jakse G, Algaba F, Malmstrom PU, Oosterlinck W. A second-look TUR in T1 transitional cell carcinoma: why? Eur Urol 2004; 45: 53946
  • 3
    Herr HW, Donat SM. Quality control in transurethral resection of bladder tumours. BJU Int 2008; 102: 12426
  • 4
    Daniltchenko DI, Riedl CR, Sachs MD et al. Long-term benefit of 5-aminolevulinic acid fluorescence assisted transurethral resection of superficial bladder cancer: 5-year results of a prospective randomized study. J Urol 2005; 174: 212933
  • 5
    Klaen R, Loy V, Huland H. Residual tumor discovered in routine second transurethral resection in patients with stage T1 transitional cell carcinoma of the bladder. J Urol 1991; 146: 3168
  • 6
    Jocham D, Witjes F, Wagner S et al. Improved detection and treatment of bladder cancer using hexaminolevulinate imaging: a prospective, phase III multicenter study. J Urol 2005; 174: 8626
  • 7
    Lange N, Jichlinski P, Zellweger M et al. Photodetection of early human bladder cancer based on the fluorescence of 5-aminolaevulinic acid hexylester-induced protoporphyrin IX: a pilot study. Br J Cancer 1999; 80: 18593
  • 8
    Zaak D, Frimberger D, Stepp H et al. Quantification of 5-aminolevulinic acid induced fluorescence improves the specificity of bladder cancer detection. J Urol 2001; 166: 16658
  • 9
    Filbeck T, Pichlmeier U, Knuechel R, Wieland WF, Roessler W. Do patients profit from 5-aminolevulinic acid-induced fluorescence diagnosis in transurethral resection of bladder carcinoma. Urology 2002; 60: 10258
  • 10
    Jichlinski P, Guillou L, Karlsen SJ et al. Hexyl aminolevulinate fluorescence cystoscopy: new diagnostic tool for photodiagnosis of superficial bladder cancer – a multicenter study. J Urol 2003; 170: 2269
  • 11
    Riedl CR, Daniltchenko D, Koenig F, Simak R, Loening SA, Pflueger H. Fluorescence endoscopy with 5-aminolevulinic acid reduces early recurrence rate in superficial bladder cancer. J Urol 2001; 165: 11213
  • 12
    Sobin LH, Wittekind C. TNM Classification of Malignant Tumors, 6th edn. Hoboken: Wiley, 2002
  • 13
    Wittekind C, Henson CE, Hutter RVP eds. TNM Supplement, 3rd edn. Hoboken: Wiley, 2003
  • 14
    Sylvester RJ, van der Meijden AP, Oosterlinck W et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006; 49: 46677
  • 15
    Babjuk M, Soukup V, Petrik R, Jirsa M, Dvoracek J. 5-aminolaevulinic acid-induced fluorescence cystoscopy during transurethral resection reduces the risk of recurrence in stage Ta/T1 bladder cancer. BJU Int 2005; 96: 798802
  • 16
    Filbeck T, Pichlmeier U, Knuechel R, Wieland WF, Roessler W. Clinically relevant improvement of recurrence-free survival with 5-aminolevulinic acid induced fluorescence diagnosis in patients with superficial bladder tumors. J Urol 2002; 168: 6771
  • 17
    Denzinger S, Burger M, Walter B et al. Clinically relevant reduction in risk of recurrence of superficial bladder cancer using 5-aminolevulinic acid-induced fluorescence diagnosis: 8-year results of prospective randomized study. Urology 2007; 69: 6759
  • 18
    Brausi M, Collette L, Kurth K et al. Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies. Eur Urol 2002; 41: 52331
  • 19
    Stenzl A, Roessler W, Fradet Y et al. Hexvix fluorescence cystoscopy improves detection and resection of papillary bladder cancer and reduces early recurrence: a multicentre, prospective, randomized study. Eur Urol Suppl 2009; 8: 373
  • 20
    Divrik RT, Yildirim U, Zorlu F, Ozen H. The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial. J Urol 2006; 175: 16414
  • 21
    Grimm MO, Steinhoff C, Simon X, Spiegelhalder P, Ackermann R, Vögeli TA. Effect of routine repeat transurethral resection for superficial bladder cancer: a long-term observational study. J Urol 2003; 170: 4337
  • 22
    Denzinger S, Wieland WF, Otto W, Filbeck T, Knuechel R, Burger M. Does photodynamic transurethral resection of bladder tumour improve the outcome of initial T1 high-grade bladder cancer? A long-term follow-up of a randomized study. BJU Int 2007; 101: 5669
  • 23
    Cheng L, Cheville JC, Neumann RM, Bostwick DG. Natural history of urothelial dysplasia of the bladder. Am J Surg Pathol 1999; 23: 4437
  • 24
    Cheng L, Cheville JC, Neumann RM, Bostwick DG. Flat intraepithelial lesions of the urinary bladder. Cancer 2000; 88: 62531
  • 25
    Schmidbauer J, Witjes F, Schmeller N, Donat R, Susani M, Marberger M. Improved detection of urothelial carcinoma in situ with hexaminolevulinate fluorescence cystoscopy. J Urol 2004; 171: 1358
  • 26
    Grossman HB, Gomella L, Fradet Y et al. A phase III, multicenter comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of superficial papillary lesions in patients with bladder cancer. J Urol 2007; 178: 627